透明细胞肾细胞癌:多期MDCT上识别PTEN表达
回顾性纳入2001-2013年103例经病理证实的透明细胞肾细胞癌,术前行四期肾脏肿块MDCT,计算病灶相对强化程度。PTEN阴性者皮髓质期相对强化显著高于PTEN阳性者(33.7 vs. 9.5,p=0.03),控制分期和大小后识别PTEN表达的准确率84%,特异度100%,敏感度11%。
要点
- PTEN阴性透明细胞肾细胞癌皮髓质期相对强化高于PTEN阳性者(33.7 vs. 9.5)。
- 控制分期和大小后,皮髓质期相对强化识别PTEN表达的准确率84%(86/103)。
- 该指标敏感度仅11%(2/19),特异度100%(84/84),阳性预测值100%(2/2)。
核心结论
- 皮髓质期相对强化可能有助于识别透明细胞肾细胞癌的PTEN表达,但需前瞻性验证。
研究设计与样本
- 回顾性研究,纳入103例经组织学证实的透明细胞肾细胞癌,术前行四期肾脏肿块MDCT,参考标准为PTEN表达。
关键影像表现/征象
- PTEN阳性和PTEN阴性透明细胞肾细胞癌均表现为皮髓质期强化峰值。
- PTEN阴性者皮髓质期相对强化显著高于PTEN阳性者(33.7 vs. 9.5,p=0.03)。
诊断标准与关键数值
- 控制病灶分期和大小后,皮髓质期相对强化识别PTEN表达的准确率84%(86/103)。
- 特异度100%(84/84),敏感度11%(2/19),阳性预测值100%(2/2),阴性预测值83%(84/101)。
临床应用与阅片要点
- 皮髓质期相对强化【(病灶最大强化值-皮质强化值)/皮质强化值×100】可能有助于提示PTEN表达状态。
- 该指标敏感度低(11%),阴性结果不能排除PTEN表达。
局限性
- 原文结论指出该指标需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate whether multiphasic MDCT enhancement profiles can help to identify PTEN expression in clear cell renal cell carcinomas (ccRCCs). Lack of PTEN expression is associated with worsened overall survival, a more advanced Fuhrman grade, and a greater likelihood of lymph mode metastasis.
METHODS: With IRB approval for this retrospective study, we derived a cohort of 103 histologically proven ccRCCs with preoperative 4-phase renal mass MDCT from 2001-2013. Following manual segmentation, a computer-assisted detection algorithm selected a 0.5-cm-diameter region of maximal attenuation within each lesion in each phase; a 0.5-cm-diameter region of interest was manually placed on uninvolved renal cortex in each phase. The relative attenuation of each lesion was calculated as [(Maximal lesion attenuation - cortex attenuation)/cortex attenuation] × 100. Absolute and relative attenuation in each phase were compared using t tests. The performance of multiphasic enhancement in identifying PTEN expression was assessed with logistic regression analysis.
RESULTS: PTEN-positive and PTEN-negative ccRCCs both exhibited peak enhancement in the corticomedullary phase. Relative corticomedullary phase attenuation was significantly greater for PTEN-negative ccRCCs in comparison to PTEN-positive ccRCCs (33.7 vs. 9.5, p = 0.03). After controlling for lesion stage and size, relative corticomedullary phase attenuation had an accuracy of 84% (86/103), specificity of 100% (84/84), sensitivity of 11% (2/19), positive predictive value of 100% (2/2), and negative predictive value of 83% (84/101) in identifying PTEN expression.
CONCLUSION: Relative corticomedullary phase attenuation may help to identify PTEN expression in ccRCCs, if validated prospectively.
引用
- Young JR, Coy H, Kim HJ, et al. Clear cell renal cell carcinoma: identifying PTEN expression on multiphasic MDCT. Abdom Radiol (NY). 2018. PMID: 29946925. doi:10.1007/s00261-018-1672-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。